TechConnect Summit 2011

Cellanyx Diagnostics

Location:NY, US
Speaker:Ashok Chander
Title:Chief Scientific Officer
Primary Industry:Biotech & Medical
Executive Summary:OCurrent cancer screening and diagnostic methods are largely qualitative and subject to human interpretation, which can often result in misdiagnosis and improper treatment. Cellaynx Diagnostics addresses this by providing oncologists with a quantitative prognostic measure of expected tumor progression. Cellaynx’s quantitative and prognostic device can improve the accuracy of diagnosis and better inform treatment decisions, leading to reduced healthcare costs, improved patient quality of life, and/or extended patient survival. ellanyx recently advanced to the Semi-Final round of the MIT 100K competition. Market Opportunity •25 million people around the world live with cancer and 11 million new cases of cancer are diagnosed each year (source: World Health Organization) •1.53 million new cancer cases arise every year in the U.S., with approximately 50% comprising lung, breast, prostate, and skin cancers (source: American Cancer Society) •The global in vitro cancer diagnostic market is projected to reach $7 billion in revenue by 2014 Revenue Model •Cellanyx will sell its technology as a package, composed of the diagnostic chip and use of the algorithmic software, to a targeted customer base of hospitals, clinics, and reference laboratories •We may also license the device and software package to biopharmaceutical companies for drug discovery purposes
Venture is:Seed Level

 

TechConnect World 2011 Nanotech 2011 Clean Technology 2011 Microtech 2011 BioNanotech 2011 TechConnect Summit 2011
Program | Exhibit/Sponsor | Press | Venue | Register
Short Courses | News | Subscribe | Contact | Site Map
© Copyright 2010 TechConnect World. All Rights Reserved.